PhRMA report shows where dollars are added to drug bills

A new report from industry trade group the Pharmaceutical Research and Manufacturers of America (PhRMA) has shed a new light on the flow of dollars through the pharmaceutical supply chain for commercially insured patients taking retail medicines.

According to PhRMA, the report details how transactions along the supply chain impact on patient costs at the pharmacy counter, and highlights the role of both the 340B Hospital Markup Program and increased consolidation and vertical integration among supply chain entities on the cost of medicines for patients and employers. 

Pointing out these hidden costs strengthens PhRMA’s arguments that people should look beyond pharma companies when apportioning blame for the high cost of medicines in the USA.